

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

**STA Ixazomib with lenalidomide and dexamethasone for
treating relapsed or refractory multiple myeloma (CDF
review of TA505) [ID1635]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final appraisal determination

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

No potential equality issues were identified during the scoping process.
--

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

Clinical experts noted that that myeloma is twice as common in people of African or Caribbean family background. However, the committee concluded that its recommendation applies equally, regardless of family background, so this difference is not in itself an equality issue.
--

- | |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|--|

No.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
Not applicable.

7. Have the committee's considerations of equality issues been described in the final appraisal determination document, and, if so, where?
Yes, see section 3.16 of the final appraisal document.

Approved by Associate Director (name): ...Linda Landells.....

Date: 14 December 2022